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INTRODUCTION
Gefitinib and/or erlotinib- induced hepatotoxicity sometimes
lead to treatment failure in EGFR mutation-positive patients with
non-small cell lung cancer (NSCLC), even though the therapeutic
effect is evident. Afatinib is a second-generation EGFR-TKI with
a metabolism different from those of gefitinib and erlotinib, al-
though severe transaminase elevation of grade3 occurs in 0.4%
of afatinib- treated patients (1). Here, we report three postoperative
NSCLC patients with recurrences who experienced severe hepa-
totoxicity while receiving gefitinib and/or erlotinib treatment but
could be safely switched to afatinib treatment.
Case 1
A 73-year-old nonsmoking female received left upper lobectomy
for adenocarcinoma of the lung (pT2aN0M0, Stage IB, EGFR : exon
21 L858R mutation) (Case 1 in Table 1). Bilateral adrenal metas-
tases occurred at 8 months after operation (Figure 1A). Gefitinib
treatment was initiated. After 8 weeks, her serum AST and ALT
had increased markedly to 253 U/L and 316 U/L, respectively
(grade 3 toxicity according to the Common Terminology Criteria
for Adverse Events (CTCAE, version 4.0) (Figure 1B) although
computed tomography (CT) revealed tumor size reductions. Next,
she received erlotinib treatment. After 6 weeks, her serum ASL
and ALT levels had increased markedly to 615 U/L and 442 U/L
(grade 3) again (Figure 1B). After the regrowth of recurrent sites,
afatinib treatment was finally commenced as a fourth- line treat-
ment at a daily dose of 20 mg at 8 months after recurrence. After
7 months of afatinib administration, CT demonstrated that the
tumor sizes were reduced without an elevation of transaminase
(Figure 1B and 1C).
Case 2
A 63-year-old nonsmoking male received right middle lobectomy
for adenocarcinoma of the lung (pT2aN1M0, Stage IIA, EGFR :
exon 21 L858R mutation) (Case 2 in Table 1). Multiple plural dis-
seminations occurred at 73 months after operation. Gefitinib treat-
ment was initiated. After 4 weeks, his serum AST and ALT had
increased markedly to 267 U/L and 414 U/L (grade 3). Afatinib
treatment was commenced as a second- line treatment at a daily
dose of 30 mg at 4 months after recurrence. After 7 months of
afatinib administration, CT revealed tumor size reductions without
an elevation of transaminase.
Case 3
A 63-year-old nonsmoking female received right upper lobec-
tomy for adenocarcinoma of the lung (pT2aN0M0, Stage IB, EGFR :
exon 19 deletion) (Case 3 in Table 1). Multiple plural dissemina-
tions, and pulmonary and mediastinal lymph node metastases
occurred with elevated carcinoembryonic antigen (CEA) at 28
months after operation. Gefitinib treatment was initiated. After 8
weeks, her serum AST and ALT had markedly increased to 397
U/L and 687 U/L (grade 3) although tumor size reductions were
evident. After regrowth of the recurrent sites, afatinib treatment
was finally commenced at a daily dose of 20 mg as a fifth- line treat-
ment at 23 months after recurrence. After 7 months of afatinib
administration, the serum CEA levels showed a marked decrease
and CT revealed tumor size reductions without an elevation of
transaminase.
DISCUSSION
This is the first report to demonstrate that afatinib treatment could
be safely and successfully performed following geftinib/erlotinib-
induced hepatotoxicity in postoperative NSCLC patients with re-
currences.
EGFR-TKIs are well known to be key therapeutic drugs for EGFR
mutation-positive NSCLC patients. However, despite their evident
therapeutic efficacy, they sometimes have to be discontinued due
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Table 1. Charactetrstics of patients
Case 1 Case 2 Case 3
Age (year)/Sex 73/F 63/M 63/F
PS 1 0 0
Smoking Never Never Never
Histology Ad Ad Ad
Operation Left upper lobectomy Right middle lobectomy Right upper lobectomy
Pathological stage IB IIA IB
EGFR-mutation Exon 21 L858R Exon 21 L858R Exon 19 delation
Recurrentsite Bilateral adrenal glands Pleural dissemination Pleural dissemination
Lung
Mediastinal lymoh node
D.F.I. (months) 8 73 28
Previous treatments 1st. Gefitinib2nd. Erlotinib
3rd. CBDCA/PEM
1st. Gefitinib 1st. CBDCA/PEM
2nd. Gefitinib
3rd. S-1
4th. DOC
Hepatotoxicity (grade) 3 3 3
Doseofafatinib (mg) 20 30 20
Duration of afatinib treatment
(months) 4 4 4
Response PR PR PR
Adverse events Paronychia (grade 2)
Diarrhea (grade 1)
Taste disturbance (grade 1)
Skin rush (grade 2)
Diarrhea (grade 1)
Paronychia (grade 1)
Ad : adenocarcinoma, PS : performance status, D.F.I. : disease free interval, CBDCA : carboplatin, PEM : pemetrexed, DOC : docetaxel, PR : partial
response
Figure 1. Clinical course in Case 1. A : Computed tomography (CT) revealed enlargement of the bilateral adrenal glands (arrows) at 8 months after
operation. B : Changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during gefitinib, erlotinib and afatinib treatment.
C : CT revealed the size reduction of recurrent sites after afatinib treatment.
Op : operation, Rec : recurrence, CBDCA/PEM : Carboplatin/Pemetrexed.
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to hepatotoxicity or other adverse events (AEs). Thus one study
reported a severe transaminase elevation of grade3 in 23.6% of
gefitinib- treated Japanese patients (the WJTOG3405 study) (2).
Afatinib is a second-generation EGFR-TKI and an irreversible in-
hibitor of all ERBB family receptor tyrosine kinases, and has
already shown favorable results for EGFR mutation-positive NSCLC
patients in the LUX-Lung 3 study (1). It also induces grade3 he-
patotoxicity in 0.4% of patients (1). However, it has a different meta-
bolic mechanism than gefitinib and erlotinib. Gefitinib and erlotinib
are metabolized in the liver by cytochrome P450 enzymes (CYP)
such as CYP3A4, with more than 80% of the administered dose
being found in feces (3). On the other hand, Stopfer et al. (4) indi-
cated that the metabolism of afatinib is negligible because it ex-
hibits high plasma protein binding of 94.6% in healthy volunteers,
and only a small fraction of the total plasma concentration is directly
exposed to hepatic metabolism and excretion. This difference has
been considered the reason why afatinib treatment exhibits much
lower hepatotoxicity compared to gefitinib/erlotinib treatment.
In case 1, both gefitinib and erlotinib were administered, and
grade 3 hepatotoxicity occurred even though the therapeutic ef-
fects were evident. Conventional chemotherapy would be chosen
before afatinib in such a case. However, in this case we judged that
an EGFR-TKI would be effective, and indeed, administration of
afatinib has so far provided a major therapeutic benefit without he-
patotoxicity. On the other hand, in cases 2 and 3, afatinib treatment
was directly chosen after the failure of gefitinib treatment, even
though erlotinib might not cause severe hepatotoxicity, because
1) the incidence of hepatotoxicity was thought to be much less,
and 2) an EGFR-TKI was expected to have an greater therapeu-
tic effect. Takimoto et al. (5) reported that polymorphisms of the
CYP2D6 gene are associated with gefitinib- and/or erlotinib- in-
duced hepatotoxicity, and thus analysis of these polymorphisms
might lead to the choice of an appropriate EGFR-TKI, and a cor-
responding reduction in drug- induced hepatotoxicity.
Kato et al. (6) analyzed just Japanese patients in the LUX-Lung
3 trial. Consequently, 75.9% Japanese patients had dose reductions
to 30 mg (33.3%) and 20 mg (42.6%) due to AEs. However,progres-
sion- free survival was significant longer with afatinib than cis-
platin/pemeterxed, indicating that the lower dose is also accept-
able in Japanese patients in terms of its efficacy. That is the reason
why we used the lower doses in these 3 patients.
At the present time, afatinib should be used as a second- line
EGFR-TKI. However, in the future, afatinib might potentially be
chosen as a first - line EGFR-TKI if its effect can be shown to be as
good as or better than gefitinib and erlotinib in LUX-Lung 7 and 8
studies.
CONCLUSION
Our case report indicated that afatinib could be a well - tolerated
EGFR-TKI that could be chosen for its relatively low hepatotoxic-
ity, which is attributable to its having a different metabolic mecha-
nism compared to other EGFR-TKIs.
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